June 8, 2012

Connie K. Ho for redOrbit.com

For the first time, scientists at Gladstone Institute have changed skin cells, imbued with a single genetic factor, into cells that can become a group of interconnecting, functional brain cells. The findings show that there may be options in combating neurological conditions. This transformation of cells would pave the way for better methods in testing drugs for neurodegenerative conditions like Alzheimers disease.

The research follows increased interest in Alzheimers disease. Currently, the disorder affects 4.5 million people in the U.S. and, by 2050, the number will have tripled. There are no medications to prevent or reverse Alzheimers Disease at this time.

The findings are published online at Cell Stem Cell and describe how the team of researchers transfer a single cell, known as Sox2, into mouse and human skin cells. Shortly, the skin cells became early-stage brain stem cells called induced neural stem cells (INSCs). The INSCs were able to self-renew and transmit electrical signals. The neurons were able to become neural networks within a month.

Many drug candidates especially those developed for neurodegenerative diseases fail in clinical trials because current models dont accurately predict the drugs effects on the human brain, commented Gladstone Investigation Dr. Yadong Huang, who is also an associate professor of neurology at the University of California, San Francisco (UCSF), in a prepared statement. Human neuronsderived from reengineered skin cellscould help assess the efficacy and safety of these drugs, thereby reducing risks and resources associated with human trials.

Huangs study was based off work done by Gladstone Investigator Dr. Shinya Yamanaka. Yanaka had four genetic factors become adult human skin cells then into embryonic stem cells, otherwise known as induced pluripotent stem cells (iPS cells). The cells can become almost any type of cell in the body. As well, last year, Gladstone Senior Investigator Dr. Sheng Ding found a combination of small molecules and genetic factors that could change skin cells into neural stem cells. These days, Huang uses one genetic factor, Sox2, to directly reprogram cell types without having to resort back to a pluripotent state.

We wanted to see whether these newly generated neurons could result in tumor growth after transplanting them into mouse brains, explained Karen Ring, UCSF Biomedical Sciences graduate student and the papers lead author, in the statement. Instead we saw the reprogrammed cells integrate into the mouses brainand not a single tumor developed.

The findings of the project have shown that Sox2 acts as a master regulator that maintains the identity of neural stem cells. In the future, Huang and his fellow researchers hope that they can identify similar regulators that can help the development of particular neural progenitors and subtypes of neurons in the brain.

If we can pinpoint which genes control the development of each neuron type, we can generate them in the petri dish from a single sample of human skin cells, noted Huang. We could then test drugs that affect different neuron typessuch as those involved in Parkinsons diseasehelping us to put drug development for neurodegenerative diseases on the fast track.

Excerpt from:
Scientists Reprogram Skin Cells To Brain Cells

Recommendation and review posted by Bethany Smith

07-06-2012 07:52 Stem cells differ from other types of cells as they are unspecialized cells that are capable of differentiating into almost any type of specialised cells. Stem cells have the ability to replace the diseased and damaged tissue in the body, without the risk of rejection and any side effects. Therapy performed using stem cells is termed as "Regenerative medicine" and has many potential benefits in treating a wide variety of diseases and injuries. The journal is the major open access forum for translational research in stem cell therapies.

Read the original post:
OMICS Group :: Journal of Stem Cell Research

Recommendation and review posted by Bethany Smith

Select a Publication: N E W S P A P E R S ---------------------------------------------- ---Alberta--- Airdrie - Airdrie Echo Banff - Banff Crag and Canyon Beaumont - Beaumont News Calgary - The Calgary Sun Camrose - Camrose Canadian Canmore - Canmore Leader Central Alberta - County Market Cochrane - Cochrane Times Cold Lake - Cold Lake Sun Crowsnest Pass - Crowsnest Pass Promoter Devon - Dispatch News Drayton - Drayton Valley Western Review Edmonton - Edmonton Examiner Edmonton - The Edmonton Sun Edson - Edson Leader Fairview - Fairview Post Fort McMurray - Fort McMurray Today Fort Saskatchewan - Fort Saskatchewan Record Grande Prairie - Daily Herald Tribune Hanna - Hanna Herald High River - High River Times Hinton - Hinton Parklander Lacombe - Lacombe Globe Leduc - Leduc Representative Lloydminster - Meridian Booster Mayerthorpe - Mayerthorpe Freelancer Nanton - Nanton News Peace Country - Peace Country Sun Peace River - Peace River Record Gazette Pincher Creek - Pincher Creek Echo Sherwood Park - Sherwood Park News Spruce Grove - Spruce Grove Examiner Stony Plain - Stony Plain Reporter Strathmore - Strathmore Standard Vermilion - Vermilion Standard Vulcan - Vulcan Advocate Wetaskiwin - Wetaskiwin Times Whitecourt - Whitecourt Star ---Manitoba--- Altona - Alton Red River Valley Echo Beausejour - Beausejour Review Carman - Carman Valley Leader Gimli - Interlake Spectator Lac Du Bonnet - Lac Du Bonnet Leader Morden - Morden Times Portage la Prairie - Portage Daily Graphic Selkirk - Selkirk Journal Stonewall - Stonewall Argus and Teulon Times Winkler - Winkler Times Winnipeg - The Winnipeg Sun ---Ontario--- Amherstburg - Amherstburg Echo Bancroft - Bancroft this Week Barrie - Barrie Examiner Barry's Bay - Barry's Bay this Week Belleville - Intelligencer Bradford - Bradford Times Brantford - Expositor Brockville - The Recorder & Times Chatham - Chatham Daily News Chatham - Chatham This Week Chatham - Today's Farmer Clinton - Clinton News-Record Cobourg - Northumberland Today Cochrane - Cochrane Times Post Collingwood - Enterprise Bulletin Cornwall - Standard Freeholder Delhi - Delhi News-Record Dresden - Leader Spirit Dunnville - Dunnville Chronicle Elliot Lake - Standard Espanola - Mid-North Monitor Fort Erie - Times Gananoque - Gananoque Reporter Goderich - Goderich Signal-Star Grand Bend - Lakeshore Advance Haliburton - Haliburton Echo Hanover - The Post Ingersoll - Ingersoll Times Innisfil - Innisfil Examiner Kapuskasing - Kapuskasing Northern Times Kenora - Kenora Daily Miner and News Kenora - Lake of the Woods Enterprise Kincardine - Kincardine News Kingston - Frontenac This Week Kingston - Kingston This Week Kingston - Kingston Whig Standard Kirkland Lake - Northern News Leamington - Leamington Post Lindsay - The Lindsay Post London - The London Free Press London - The Londoner Lucknow - Lucknow Sentinel Midland - Free Press Minden - Minden Times Mitchell - Mitchell Advocate Napanee - Napanee Guide Niagara-on-the-Lake - Niagara Advance Niagara Falls - Review Niagara Falls - Niagara Shopping News Niagara Falls - W. Niagara Community Newspapers North Bay - North Bay Nugget Northumberland - Northumberland Today Norwich - Norwich Gazette Orillia - Packet and Times Ottawa - The Ottawa Sun Owen Sound - Sun Times Oxford - Oxford Review Paris - Paris Star Online Pelham - Pelham News Pembroke - Daily Observer Peterborough - Peterborough Examiner Petrolia - Petrolia Topic Picton - County Weekly News Port Colborne - Inport News Port Hope - Northumberland Today Port Elgin - Shoreline Beacon Sarnia - Observer Sarnia - Sarnia This Week Sault Ste Marie - Sault Star Sault Ste Marie - Sault This Week Seaforth - Seaforth Huron Expositor Simcoe - Simcoe Reformer St. Catharines - St. Catharines Shopping News St. Catharines - Standard St. Thomas - St. Thomas Times-Journal Stirling - Community Press Stratford - The Beacon Herald Strathroy - Strathroy Age Dispatch Sudbury - Sudbury Star Thorold - Thorold News Tillsonburg - Tillsonburg News Timmins - Daily Press Timmins - Timmins Times Toronto - The Toronto Sun Trenton - Trentonian Wallaceburg - Wallaceburg Courier Press Welland - Tribune Welland - Welland News West Lorne - The Chronicle Wiarton - Wiarton Echo Woodstock - Sentinel Review ---Saskatchewan--- Meadow Lake - Meadow Lake Progress Melfort - Melfort Journal Nipawin - Nipawin Journal MAGAZINES & SPECIALTY PUBLICATIONS --------- Biz Magazine Business London Cottage Home and Property Showcase Food and Wine Show Hamilton Halton Weddings Hamilton Magazine InterVin International Wine Awards Kingston Life London Citylife Muskoka Magazine Muskoka Trails Niagara Food and Wine Expo Niagara Magazine Ontario Farmer Ontario Golf Sault Good Life Simcoe Life The Home Show Vines Magazine What's Up Muskoka

Read more:
Stem cell therapy offers new treatment options for pets -- and humans

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Dublin - Research and Markets (http://www.researchandmarkets.com/research/p4qg7d/molecular_and_cell) has announced the addition of John Wiley and Sons Ltd's new book "Molecular and Cellular Therapeutics" to their offering.

Molecular and Cellular Therapeutics aims to bring together key developments in the areas of molecular diagnostics, therapeutics and drug discovery. The book covers topics including diagnostics, therapeutics, model systems, clinical trials and drug discovery. The developing approaches to molecular and cellular therapies, diagnostics and drug discovery are presented in the context of the pathologies they are devised to treat.

Key Topics Covered:

1 Cytochrome P450 pharmacogenetics: from bench to bedside

2 Cancer biomarkers for diagnosis, prognosis and therapy

3 HER2 targeted therapy-induced gastrointestinal toxicity: from the clinical experience to possible molecular mechanisms

4 Antibody-targeted photodynamic therapy

5 Anti-ageing strategy of the lung for chronic inflammatory respiratory disease - targeting protein deacetylases

6 RNA interference: from basics to therapeutics

Read the original post:
Research and Markets: Molecular and Cellular Therapeutics

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/xp9wx4/pharmacogenetics_a) has announced the addition of John Wiley and Sons Ltd's new book "Pharmacogenetics and Individualized Therapy" to their offering.

The One-Stop Reference To Pharmacogenetics And Its Impact On Pharmaceuticals, Therapeutics, And Clinical Practices

Pharmacogenetics and Individualized Therapy offers thorough coverage of the study of the genetic determinants of drug response at the single gene leveland its impact on pharmaceuticals, therapeutics, and clinical practice. Providing an overview of the molecular basis of pharmacogenetics, the book helps readers understand the implications of genetic variability on pharmacokinetics and pharmacodynamics, as well as other aspects such as adverse drug reactions. Providing coverage of specific disease areas, including cardiovascular concerns, cancer and asthma/COPD, transplantation, and pain medication, the book also looks at the clinical practices, along with the psychiatric and ethical issues that have come to dominate conversation about pharmacogenetics.

The technological applications of pharmacogenetics, including genotyping, drug disposition (metabolism and enzymes), and the impact of this research on the pharmaceutical industry and regulatory matters are all addressed in chapters by internationally recognized leaders from both academia and industry.

Including chapters on specific therapeutic areas and clinical aspects, Pharmacogenetics and Individualized Therapy helps readers, whether they're students or researchers, to understand the implications of genetic variability on pharmacokinetics and pharmacodynamics.

Authors

ANKE-HILSE MAITLAND-van der ZEE, PhD, is Associate Professor of Pharmacogenetics

Pharmacogenomics at Utrecht University, the Netherlands.

ANN K. DALY, PhD, is Professor of Pharmacogenetics at Newcastle University, UK.

See more here:
Research and Markets: Pharmacogenetics and Individualized Therapy

Recommendation and review posted by Bethany Smith

(CBS News) Parents designing babies is "a real risk" in the wake of new research that's given scientists the ability to map the genetic code of a fetus, according to Dr. Eric Schadt, chairman of the Genetics Department at New York's Mount Sinai Medical Center.

He said the test that requires only a blood sample from the mother and saliva from the father to diagnose more than 3,000 genetic disorders before a baby is born is a positive thing, but brings up many ethical and social questions that need to be discussed prior to the test's use, such as the potential for abortion for a variety of reasons following the test.

Schadt said on "CBS This Morning" that the test, utilized in a University of Washington study, will be available for wide use in five years or more. Until then, he said, it needs to be talked about extensively.

Researchers sequence fetus' entire genome from mom's blood and dad's saliva

He explained, "As we go through, how do we adapt to that kind of testing, the social implications; what sorts of policies should we be thinking about? Those are the discussions we should be having right now about how to leverage this information in ways that are benefiting humankind, not biasing the type of population through unnatural selection of traits."

Schadt said education of the general population and lawmakers on what's coming is needed to prevent what he called an "extreme designer baby mentality."

When asked if new laws are needed to avoid designing babies on traits not based on health, Schadt said, "It's not unlike choosing to terminate a pregnancy based on the sex of the child. Those are the sorts of things we want to avoid."

For more with Schadt on the test, watch the video in the player above.

Go here to read the rest:
Expert on gene test: Baby designing a real risk

Recommendation and review posted by Bethany Smith

SAN FRANCISCO--Genetic engineering could hold the key to artificially creating semiconductors in a lab. According to technology news site Ars Technica, a team of academics at the University of California, Santa Barbara is looking at ways to create synthetic proteins that could form new structures of silicon dioxide to make computer chips with.

These chips would then be used in all kinds of electronics.

The proteins could also form titanium dioxide, used in solar cells.

The process is a bit different from regular genetic engineering because it uses synthetic cells made of the randomly combined genes of two related silicateins replete with random mutations, surrounded by a nucleus of minute plastic beads.

The artificial cells are put through the proverbial wringer, killing many along the way. Those that survive the process have their genes cherry picked by the scientists from either the silicon or titanium dioxide-forming proteins.

The results were somewhat surprising, with researchers finding not just the original silicateins used to form the artificial cell in the first place, but also another, different gene.

Tests on the new gene found it contained a silica-forming protein which has been dubbed silicatein X1, which may prove useful in the making of folded sheets of silica-protein fibers.

Silica skeletons of radiolaria in false color

Now that scientists know its possible to create entirely different silica proteins, the next step will be to change the conditions in order to achieve things like semiconductor performance.

Here is the original post:
Genetic engineering for synthetic semiconductors

Recommendation and review posted by Bethany Smith

Patients who have genetic testing done to detect their risk for multiple health conditions do not use more health services after testing than those who elect not to be checked, says a study published online May 17 in Genetics in Medicine.

Genetic tests increasingly are being marketed directly to patients, raising concerns among some physicians that they could cause a spike in patients requesting unnecessary screening and procedures, said Robert J. Reid, MD, PhD, lead study author and associate investigator with Group Health Research Institute in Seattle.

Certainly, there is a lot of concern in the country that doing indiscriminate testing of individuals around their genetic susceptibility will alarm them and increase demand, he said.

Researchers studied 1,599 insured patients between age 25 and 40 from the Henry Ford Health System in Detroit. Of those, 217 opted to get genetic tests. Patients who received the tests had more specialty physician visits before the checks than the untested group, but the study found no change in overall use of health care services among those who had the evaluations done and those who did not (ncbi.nlm.nih.gov/pubmed/22595941/).

Researchers analyzed health care usage by participants for 12 months before and 12 months after genetic testing. Dr. Reid said the study took a conservative approach. It looked only at screening and procedures associated with four of eight conditions whose risk could be detected from the multiplex genetic susceptibility tests: type 2 diabetes mellitus, atherosclerotic coronary heart disease, colorectal cancer and lung cancer. Also, the tests were thoroughly explained to all study participants something that doesnt necessarily happen in everyday practice, Dr. Reid said.

They certainly had a fair amount of material on which to base their decision, and they had follow-up to help them understand the results, he said. In most cases there is not a lot of counseling beforehand or a lot of explanation afterward.

One surprising factor was how few patients opted to have the testing done, Dr. Reid said.

Blacks were significantly less likely than whites to choose testing, as were those with just a high school education or less. The age group studied could be a factor, as younger individuals may feel that such tests offer little value at that stage in their lives, he said.

More research needs to be done to determine how genetic tests impact behavior in larger groups of patients. Such tests may have a positive impact by motivating some patients to make healthier lifestyle choices.

If someone is told they are at risk for heart disease or diabetes, it might prompt them to maintain a healthy body weight, try to lower their cholesterol or stop smoking, Dr. Reid said. I think that is the next stage to see if it promotes positive health behavior.

See the original post here:
Genetic testing doesn’t drive up demand for more health services

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/3lsg2r/forwardtime_popul) has announced the addition of John Wiley and Sons Ltd's new book "Forward-Time Population Genetics Simulations: Methods, Implementation, and Applications" to their offering.

The only book available in the area of forward-time population genetics simulationsapplicable to both biomedical and evolutionary studies

The rapid increase of the power of personal computers has led to the use of serious forward-time simulation programs in genetic studies. Forward-Time Population Genetics Simulations presents both new and commonly used methods, and introduces simuPOP, a powerful and flexible new program that can be used to simulate arbitrary evolutionary processes with unique features like customized chromosome types, arbitrary nonrandom mating schemes, virtual subpopulations, information fields, and Python operators.

The book begins with an overview of important concepts and models, then goes on to show how simuPOP can simulate a number of standard population genetics modelswith the goal of demonstrating the impact of genetic factors such as mutation, selection, and recombination on standard Wright-Fisher models. The rest of the book is devoted to applications of forward-time simulations in various research topics.

Key Topics Covered:

1. Basic concepts and models

2. Simulation of population genetics models

3. Ascertainment bias in population genetics

4. Observing properties of evolving populations

Here is the original post:
Research and Markets: Forward-Time Population Genetics Simulations: Methods, Implementation, and Applications

Recommendation and review posted by Bethany Smith

SAN FRANCISCO Scientists at the UCSF-affiliated Gladstone Institutes have for the first time transformed skin cells with a single genetic factor into cells that develop on their own into an interconnected, functional network of brain cells.

The research offers new hope in the fight against many neurological conditions because scientists expect that such a transformation orreprogramming of cells may lead to better models for testing drugs for devastating neurodegenerative conditions such as Alzheimers disease.

This research comes at a time of renewed focus on Alzheimers disease, which currently afflicts 5.4 million people in the United States alone a figure expected to nearly triple by 2050. Yet there are no approved medications to prevent or reverse the progression of this debilitating disease.

In findings appearing online today inCell Stem Cell, researchers in the laboratory of Gladstone investigator Yadong Huang, M.D., Ph.D., describe how they transferred a single gene called Sox2 into both mouse and human skin cells. Within days the skin cells transformed into early-stage brain stem cells, also called induced neural stem cells (iNSCs). These iNSCs began to self-renew, soon maturing into neurons capable of transmitting electrical signals. Within a month, the neurons had developed into neural networks.

Many drug candidates especially those developed for neurodegenerative diseases fail in clinical trials because current models dont accurately predict the drugs effects on the human brain, said Huang, who also is an associate professor of neurology at UCSF. Human neurons derived from reengineered skin cells could help assess the efficacy and safety of these drugs, thereby reducing risks and resources associated with human trials.

Huangs findings build on the work of other Gladstone scientists, starting with Gladstone investigator Shinya Yamanaka, M.D., Ph.D. In 2007, Yamanaka used four genetic factors to turn adult human skin cells into cells that act like embryonic stem cells called induced pluripotent stem cells.

Also known as iPS cells, these cells can become virtually any cell type in the human body just like embryonic stem cells. Then last year, Gladstone senior investigatorSheng Ding, PhD, announced that he had used a combination of small molecules and genetic factors to transform skin cellsdirectlyinto neural stem cells. Today, Huang takes a new tack by using one genetic factor Sox2 to directly reprogram one cell type into another without reverting to the pluripotent state.

Avoiding the pluripotent state as Drs. Ding and Huang have done is one approach to avoiding the potential danger that rogue iPS cells might develop into a tumor if used to replace or repair damaged organs or tissue.

We wanted to see whether these newly generated neurons could result in tumor growth after transplanting them into mouse brains, said Karen Ring, UCSF Biomedical Sciences graduate student and the papers lead author. Instead we saw the reprogrammed cells integrate into the mouses brain and not a single tumor developed.

This research has also revealed the precise role of Sox2 as a master regulator that controls the identity of neural stem cells. In the future, Huang and his team hope to identify similar regulators that guide the development of specific neural progenitors and subtypes of neurons in the brain.

Originally posted here:
Scientists reprogram skin cells into brain cells

Recommendation and review posted by sam

By Rob Waugh

PUBLISHED: 11:00 EST, 7 June 2012 | UPDATED: 11:01 EST, 7 June 2012

A single genetic tweak is all that is needed to turn ordinary skin cells into functioning brain cells, scientists have shown

A single genetic tweak is all that is needed to turn ordinary skin cells into functioning brain cells, scientists have shown.

The research could help to treat Alzheimers, Parkinsons and other brain diseases.

Working in the laboratory, US scientists transferred a single gene called Sox2 into both mouse and human skin cells.

Within days the cells transformed themselves into early-stage brain stem cells.

These induced neural stem cells (iNSCs) then began to self-renew and mature, eventually becoming neurons capable of transmitting electrical signals.

In less than a month the cells had developed neural networks. Transplanted into mouse brains, they functioned without any adverse side effects, such as tumour growth.

Lead researcher Dr Yadong Huang, from the Gladstone Institutes in San Francisco, California, said: Many drug candidates, especially those developed for neurodegenerative diseases, fail in clinical trials because current models dont accurately predict the drugs effects on the human brain.

Go here to read the rest:
New hope for Alzheimer's sufferers as breakthrough allows scientists to grow new brain cells from normal skin

Recommendation and review posted by sam

June 8, 2012

Connie K. Ho for redOrbit.com

For the first time, scientists at Gladstone Institute have changed skin cells, imbued with a single genetic factor, into cells that can become a group of interconnecting, functional brain cells. The findings show that there may be options in combating neurological conditions. This transformation of cells would pave the way for better methods in testing drugs for neurodegenerative conditions like Alzheimers disease.

The research follows increased interest in Alzheimers disease. Currently, the disorder affects 4.5 million people in the U.S. and, by 2050, the number will have tripled. There are no medications to prevent or reverse Alzheimers Disease at this time.

The findings are published online at Cell Stem Cell and describe how the team of researchers transfer a single cell, known as Sox2, into mouse and human skin cells. Shortly, the skin cells became early-stage brain stem cells called induced neural stem cells (INSCs). The INSCs were able to self-renew and transmit electrical signals. The neurons were able to become neural networks within a month.

Many drug candidates especially those developed for neurodegenerative diseases fail in clinical trials because current models dont accurately predict the drugs effects on the human brain, commented Gladstone Investigation Dr. Yadong Huang, who is also an associate professor of neurology at the University of California, San Francisco (UCSF), in a prepared statement. Human neuronsderived from reengineered skin cellscould help assess the efficacy and safety of these drugs, thereby reducing risks and resources associated with human trials.

Huangs study was based off work done by Gladstone Investigator Dr. Shinya Yamanaka. Yanaka had four genetic factors become adult human skin cells then into embryonic stem cells, otherwise known as induced pluripotent stem cells (iPS cells). The cells can become almost any type of cell in the body. As well, last year, Gladstone Senior Investigator Dr. Sheng Ding found a combination of small molecules and genetic factors that could change skin cells into neural stem cells. These days, Huang uses one genetic factor, Sox2, to directly reprogram cell types without having to resort back to a pluripotent state.

We wanted to see whether these newly generated neurons could result in tumor growth after transplanting them into mouse brains, explained Karen Ring, UCSF Biomedical Sciences graduate student and the papers lead author, in the statement. Instead we saw the reprogrammed cells integrate into the mouses brainand not a single tumor developed.

The findings of the project have shown that Sox2 acts as a master regulator that maintains the identity of neural stem cells. In the future, Huang and his fellow researchers hope that they can identify similar regulators that can help the development of particular neural progenitors and subtypes of neurons in the brain.

If we can pinpoint which genes control the development of each neuron type, we can generate them in the petri dish from a single sample of human skin cells, noted Huang. We could then test drugs that affect different neuron typessuch as those involved in Parkinsons diseasehelping us to put drug development for neurodegenerative diseases on the fast track.

Read the original:
Scientists Reprogram Skin Cells To Brain Cells

Recommendation and review posted by sam

PerkinElmer (NYSE:PKI), a provider of life sciences tools and services, is launching a new Personalized Health Innovation Center of Excellence at an existing facility in Hopkinton, Mass. The creation of the center will add 100 workers to the Hopkinton operation, to a total of 350, through both new hires and relocating some existing personnel from other facilities. The Center will focus on accelerating scientific discoveries to help biotechnology researchers working on both personalized medicine drugs and diagnostic tools that help determine which patients will benefit most from which drugs. The center will be fully up and running before the end of the year, PerkinElmer executives said. The Hopkinton facility was previously the headquarters of Caliper Life Sciences, which was acquired by PerkinElmer last year for $600 million. The facility now houses the headquarters for the PerkinElmer Life Sciences and Technology business. We are delighted to establish our new Center of Excellence, which will serve as an exciting example of PerkinElmers commitment to, and culture of, innovation, Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer, said. It will act as a foundation and catalyst for future advances in personalized health, as it concentrates the knowledge of our life sciences R&D and commercial leaders for greater scientific collaboration.

The center will bring together researchers from several teams including chemistry, biochemistry, cell biology, molecular biology and reagent development.

Read the original post:
PerkinElmer to open new Personalized Medicine Center

Recommendation and review posted by sam

Mike Schroeder had the opportunity to meet and visit with Larry the Cable Guy. Larry and his wife are big contributors to Madonna Rehabilitation Hospital at Lincoln, Neb. where Mike is currently going through rehab for his spinal cord injuries.

A spinal cord injury which occurred early this spring has left Mike paralyzed. He nor his family will ever give up hope that someday he will walk again.

Currently he is at Madonna Rehabilitation Hospital in Lincoln, Neb. where he is working extremely hard to learn things he once took for granted. Madonna is one of the nation's foremost facilities for medical rehabilitation and research. Specializing in traumatic brain injury, spinal cord injury and pediatric rehabilitation, Madonna offers hope and healing to thousands of patients from throughout the country each year.

Madonna's team of highly specialized physiatrists, therapists, rehabilitation nurses and clinicians work with the most advanced technology and equipment to help each person achieve the highest level of independence.

Mike has come a long way.

He was on a ventilator for a few days following the accident and had slight movement in his arms when he arrived; now he is able to use his hands and has some sensation in his feet and legs.

He spends several hours a day working with an occupational therapist, physical therapist and recreational therapist. He works hard. Very hard. He is determined to make his life the best it can be.

He is learning how to do things such as putting on shoes and socks, relearning how to eat and shave and how to shower, things he has always taken for granted that he knew how to do without assistance.

He also works on his balance - something that has come a long way. "You take for granted that you are going to be able to sit without falling," he said, explaining that he toppled over many times at first because his muscles no longer do the job for him. He is building up his arm muscles - and hoping for football lineman arms - which are used in many ways including in the transferring process.

His recreational therapist is showing Mike that he can go out in public in his wheelchair and still enjoy fun activities (they have gone bowling and fishing.)

Follow this link:
'It is what it is'

Recommendation and review posted by sam

by Claude Solnik Published: June 8, 2012 Tags: Long Island, Multiple sclerosis, New York, NextStep Fitness, paralysis, spinal cord injuries, Stony Brook University

NextStep Fitness founder Janne Kouri (seated)

Stony Book is collaborating with Los Angeles-basedNextStep Fitness to build the organizations first fitness and wellness facility in New York for people with paralysis and spinal cord injuries.

Stony Brooks School of Health Technology and Management is helping the California firm develop the facility, which would be located at and connected to the university.

The Stony Brook facility will be the first NextStep location linked to an academic research center, which has the expertise to quickly disseminate important research findings related to fitness and wellness facilities, Stony Brook President Samuel Stanley said.

NextStep, a nonprofit founded by Janne Kouri, a former Georgetown University football player paralyzed in a swimming accident in 2006, hopes to raise $1.5 million to launch the facility at Stony Brook, to be named NextStep Fitness Center at Stony Brook Medicine.

Stony Brook estimates there are 80,000 people with spinal cord injuries nationwide, with 600 injuries a year occurring in New York. There are another 9,000 people with multiple sclerosis.

There are no acute spinal cord rehabilitation facilities located in New York state, said Craig Lehman, dean of the School of Health Technology and Management. People with spinal cord injuries must travel to Manhattan or New Jersey to get the level of rehabilitative care they need.

The NextStep facility at Stony Brook be the only one of its kind in the state and the first planned in addition to the original Los Angeles facility. The nonprofit, which hopes to open locations around the country, also is planning a facility for the Washington, D.C., area.

More here:
Stony Brook to build spinal cord injury rehab center

Recommendation and review posted by sam

CLEARWATER, FL--(Marketwire -06/08/12)- Biostem U.S., Corporation, (HAIR) (HAIR) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, today reported that it has engaged Acropolis Inc. http://www.acropolisinc.com, a full-service advertising agency located in Orlando, Florida, to lend their expertise in brand building, marketing, and advertising development and placement.

Biostem Chief Executive Officer Dwight Brunoehler stated, "After several months of interviewing prospective agencies, we have come to the conclusion that Acropolis is the one to assist us in executing our plans. Their notable work in multiple media areas is impressive, to say the least. Their client list including The University of Florida, Arby's Restaurants, and the City of Orlando, speaks for itself."

Acropolis Principal, Scott Major, said, "This is a great fit for Acropolis. Our entire team loves the Biostem business approach in the incredible field of regenerative medicine. The hair re-growth field in which we will be marketing the Biostem technology is enormous. We are pleased to be a part of Biostem's expansion."

About Biostem U.S. CorporationBiostem U.S., Corporation is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S., Corporation is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

For further information, contact Fox Communications Group at 310-974-6821, or view the Biostem website at http://www.biostemus.com.

See the rest here:
Biostem U.S., Corporation Engages Acropolis Agency to Assist in Implementing Its International Marketing Plan

Recommendation and review posted by sam

LEUVEN, BELGIUM--(Marketwire -06/08/12)- TiGenix (EURONEXT:TIG)

TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect

TiGenix (EURONEXT:TIG) announced today that its innovative cartilage repair therapy ChondroCelect has obtained national reimbursement in the Netherlands. The Dutch National Health Authority (NZa) has formally announced that ChondroCelect is to receive national reimbursement retroactively per January 1, 2012. Previously ChondroCelect was made available in the Netherlands under a risk-sharing scheme.

"We are delighted with the decision of the NZa to reimburse ChondroCelect, and look forward to working with Dutch orthopedic centers of excellence and health insurers to routinely make this breakthrough therapy available to the right patients in the Netherlands," said Eduardo Bravo, CEO of TiGenix. "Dutch clinicians and scientists have been instrumental in ChondroCelect's development and four Cartilage Expert Centers in the Netherlands have already gained extensive experience with the procedure. After having obtained national reimbursement in Belgium last year, this constitutes another major step in improving patient access to this innovative therapy. We remain optimistic that we can obtain national reimbursement in other European countries later this year."

About TiGenix

TiGenix NV (EURONEXT:TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com.

About ChondroCelect

ChondroCelect is the first and currently only cell therapy that has been granted market authorisation by the European Union in accordance with the Advanced Therapy Medicinal Product regulation EC1394/2007. For more information, including the European Public Assessment Report (EPAR), prescribing information, and the Summary of Product Characteristics (SPC) please visit the European Medicines Agency (EMA) website at http://www.ema.europa.eu.

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

Original post:
TiGenix: National Reimbursement in the Netherlands Obtained for Breakthrough Cartilage Therapy ChondroCelect(R)

Recommendation and review posted by simmons

7 June 2012

Bone Marrow Transplant Milestone

Today is a big day for the Waikato Hospital Haematology Department and equally big for consultant haematologist Dr Humphrey Pullon who established the transplant service there 20 years ago.

The first autologous bone marrow transplant was carried out at Waikato Hospital on 25 June 1992 and was today celebrated with a patient afternoon tea, which about 120 transplant recipients attended.

By the end of the month we will have performed 317 transplants in 301 patients over the past 20 years, said Dr Pullon.

The first patient went down to Wellington to have her stem cells collected and they were then driven back up to be stored here She is still alive, but was unable to attend today.

We did the stem cell collection of the second patient, who is sadly no longer alive, and our third patient was cured of Lymphoma as a result of his transplant.

The third patient was Lloyd Given of Tauranga who attended todays afternoon tea.

I would like to extend my thanks to Waikato Hospital, Humphrey and the oncologist at the time, Grant Trotter, he said.

The autologous bone marrow transplant process is a long and involved one.The cancer patient is treated and goes into remission or gets to a point where the cancer is well controlled.

Read the original:
Bone Marrow Transplant Milestone

Recommendation and review posted by Bethany Smith

07-06-2012 07:39 Cell being the smallest part of any organism, is a building block of life. Cell therapies often focus on the treatment of hereditary diseases, with methods of gene therapy. The journal describes biology of a cell and the process of pioneering new cells into a tissue in order to negotiate a disease.

Originally posted here:
OMICS Group :: Journal of Cell Science

Recommendation and review posted by Bethany Smith

Regulated information June 8, 2012

TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect

Leuven (BELGIUM) - June 8, 2012 - TiGenix (NYSE Euronext: TIG) announced today that its innovative cartilage repair therapy ChondroCelect has obtained national reimbursement in the Netherlands. The Dutch National Health Authority (NZa) has formally announced that ChondroCelect is to receive national reimbursement retroactively per January 1, 2012. Previously ChondroCelect was made available in the Netherlands under a risk-sharing scheme.

"We are delighted with the decision of the NZa to reimburse ChondroCelect, and look forward to working with Dutch orthopedic centers of excellence and health insurers to routinely make this breakthrough therapy available to the right patients in the Netherlands," said Eduardo Bravo, CEO of TiGenix. "Dutch clinicians and scientists have been instrumental in ChondroCelect`s development and four Cartilage Expert Centers in the Netherlands have already gained extensive experience with the procedure. After having obtained national reimbursement in Belgium last year, this constitutes another major step in improving patient access to this innovative therapy. We remain optimistic that we can obtain national reimbursement in other European countries later this year."

For more information: Eduardo Bravo Chief Executive Officer eduardo.bravo@tigenix.com

Claudia D`Augusta Chief Financial Officer claudia.daugusta@tigenix.com Hans Herklots Director Investor & Media Relations hans.herklots@tigenix.com +32 16 39 60 97

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG)is a leading European cell therapy companywith a marketed product for cartilage repair, ChondroCelect, and a strongpipeline with clinical stage allogeneic adult stem cell programsfor the treatment ofautoimmune and inflammatory diseases.TiGenixis based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (theNetherlands). For more information please visitwww.tigenix.com.

About ChondroCelect

See the original post:
TiGenix : national reimbursement in the Netherlands obtained for breakthrough cartilage therapy ChondroCelect®

Recommendation and review posted by Bethany Smith

06-06-2012 19:15 A research team led by Dr. Seung Hoon Lee took part in a multinational genome research project, consisting of researchers from fifty different nations. The project's findings identifying 56 genes involved in osteoporosis and fracture risk were published on April16th in Nature Genetics. In the largest-scale genetic research project to date, genetic testing was done on 210000 individuals from around the world. The study included clinical data from Korea, such as bone density measures and DNA samples from fourteen hundred patients. The study was able to identify 56 genetic variants, including WNT16, that influence bone density, of which 14 were associated with fracture risk. Dr. Seung Hoon Lee / Dept. of Endocrinology/Metabolism If individuals with high fracture risk can be identified by detecting this kind of high-risk gene, in addition to other clinical risk factors and bone density measurements in accordance with current treatment standards, the study suggests that prevention and treatment using individually-tailored drugs will be possible. Osteoporosis is a skeletal disease of increased risk of fracture due to weakened bone strength. Although this age-related disease is silent and asymptomatic until fractures occur, it has a high incidence and devastating consequences. By identifying genes related to osteoporosis and fracture risk, this multinational genetic study is expected to lead to new breakthroughs in the treatment of osteoporosis.

Read this article:
Genes associated with osteoporosis and fracture risk identified - Video

Recommendation and review posted by Bethany Smith

Public release date: 7-Jun-2012 [ | E-mail | Share ]

Contact: Jim Fessenden james.fessenden@umassmed.edu 508-856-2000 University of Massachusetts Medical School

WORCESTER, MA Degeneration of the axon and synapse, the slender projection through which neurons transmit electrical impulses to neighboring cells, is a hallmark of some of the most crippling neurodegenerative and brain diseases such as amyotrophic lateral sclerosis (ALS), Huntington's disease and peripheral neuropathy. Scientists have worked for decades to understand axonal degeneration and its relation to these diseases. Now, researchers at the University of Massachusetts Medical School are the first to describe a gene dSarm/Sarm1 responsible for actively promoting axon destruction after injury. The research, published today online by Science, provides evidence of an exciting new therapeutic target that could be used to delay or even stop axon decay.

"This discovery has the potential to have a profound impact on our understanding of neurodegenerative diseases, much like the discovery of apoptosis (programmed cell death) fundamentally changed our understanding of cancer," said Marc R. Freeman, PhD, associate professor of neurobiology at the University of Massachusetts Medical School and lead investigator on the study. "Identification of this gene allows us to start asking exciting new questions about the role of axon death in neurodegenerative diseases. For example, is it possible that these pathways are being inappropriately activated to cause premature axon death?"

For more than a century, scientists believed that injured axons severed from the neuron cell body passively wasted away due to a lack of nutrients. However, a mouse mutation identified in the early 1990s called slow Wallerian degeneration (Wlds) was able to suppress axon degeneration for weeks. This finding forced scientists to reassess Wallerian degeneration, the process through which an injured axon degenerates, as a passive process and consider the possibility that an active program of axon auto-destruction, akin to apoptotic death, was at work instead.

If Wallerian degeneration was an active process, hypothesized Dr. Freeman, a Howard Hughes Medical Institute Early Career Scientist, then it should be possible through forward genetic screens in Drosophila to identify mutants exhibiting Wlds-like axon protection. Freeman and colleagues screened more than 2,000 Drosophila mutants for ones that exhibited long-term survival of severed axons. Freeman says this was a heroic effort on the part of his colleagues. The screen took place over the next two and a half years, and involved seven students and post-docs in the Freeman labJeannette M. Osterloh, A. Nicole Fox, PhD, Michelle A. Avery, PhD, Rachel Hackett, Mary A. Logan, PhD, Jennifer M. MacDonald, Jennifer S. Zeigenfusswho performed the painstaking and labor-intensive experiments needed on each Drosophila mutant to identify flies that suppressed axonal degeneration after nerve injury.

Through these tests, they identified three mutants (out of the 2,000 screened) where severed axons survived for the lifespan of the fly. Next generation sequencing and chromosome deficiency mapping techniques were then used to isolate the single gene affected in all three dSarm. These were loss-of-function alleles, meaning that Drosophila unable to produce the dSarm/Sarm1 molecule exhibited prolonged axon survival for as many as 30 days after injury. Freeman and colleagues went on to show that mice lacking Sarm1, the mammalian homolog of dSarm, also displayed remarkable preservation of injured axons. These findings provided the first direct evidence that Wallerian degeneration was driven by a conserved axonal death program and not a passive response to axon injury.

"For 20 years people have been looking for a gene whose normal function is to promote axon degeneration," said Osterloh, first author on the study. "Identification of the dSarm/Sarm1 gene has enormous therapeutic potential, for example as a knockdown target for patients suffering from diseases involving axonal loss."

The next step for Freeman and colleagues is to identify additional genes in the axon death pathway and investigate whether any have links with specific neurodegenerative diseases. "We're already working with scientists at UMMS to understand the role axon death plays in ALS and Huntington's disease," said Freeman. "We are very excited about the possibility that these findings could have broad therapeutic potential in many neurodegenerative diseases."

###

Originally posted here:
Scientists identify first gene in programmed axon degeneration

Recommendation and review posted by Bethany Smith

ScienceDaily (June 7, 2012) A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.

The study was published online in the journal Disease Models & Mechanisms and will appear in the November 2012 print edition in an article titled, "Initiation of prostate cancer in mice by Tp53R270H: Evidence for an alternate molecular progression."

"Our team found a molecular pathway to prostate cancer that differs from the current conventional wisdom of how the disease develops," said Alexander Borowsky, associate professor of pathology and laboratory medicine and principal investigator of the study. "With this new understanding, research can go in new directions to possibly develop new diagnostics and refine therapy."

Prostate cancer is the leading cancer diagnosis in men in the United States. Although it is curable in about 80 percent of men with localized disease, the rate is much lower if the cancer is highly virulent and has spread beyond the prostate gland.

The investigators developed a mouse model genetically engineered to have a mutation in the "tumor suppressor" gene, p53, specifically in the cells of the prostate gland. These mice were significantly more likely to develop prostate cancer than control mice without the mutation, and provided the first indication that the p53 mutation could be involved in the initiation of prostate cancer. They also note that the mutation of p53 in the prostate differs from loss or "knock-out" of the gene, which suggests that the mechanism is more complicated than simply a "loss of tumor suppression" and appears to involve an actively oncogenic function of the mutant gene.

The p53 gene encodes for a protein that normally acts as a tumor suppressor, preventing the replication of cells that have suffered DNA damage. Mutation of the gene, which can occur through chemicals, radiation or viruses, causes cells to undergo uncontrolled cell division. The p53 mutation has been implicated in the initiation of other malignancies, including breast, lung and esophageal cancers.

Other studies have associated p53 mutation with disease progression in prostate cancer, but this is the first to find that it can have a role in the early initiation of prostate cancer, as well.

Until now, understanding of the role of p53 was that mutation occurred exclusively as a late event in the course of prostate cancer. Based on the findings in the new mouse model that the researchers developed, p53 mutation not only can initiate prostate cancer but might also be associated with early progression toward more aggressive forms of the disease.

Genetic mutations can initiate cancers in a variety of ways. Those include promotion of uncontrolled cell growth and loss of the gene's normal cell growth-suppressor functions. Exactly how the p53 mutation promotes the initiation and progression of prostate cancer remains to be clarified and is a focus of current research by the UC Davis team. They also are trying to gain an understanding of how the p53 mutation affects the effectiveness of standard treatments for prostate cancer, such as radiation and hormone therapy.

Another application of the discovery could be the development of a new diagnostic test for prostate cancer based on the presence of the p53 mutation as a biomarker.

Read the original post:
New role for p53 genetic mutation -- initiation of prostate cancer

Recommendation and review posted by Bethany Smith

Scientists map babys genetic code in womb

By John von Radowitz

Friday, June 08, 2012

An unborn babys whole genetic code has been mapped in the womb using DNA taken from its parents.

The technique could in future make it possible to swiftly scan for some 3,500 genetic disorders before birth, without physically disturbing either foetus or mother.

But scientists acknowledge the ability to sequence a babys whole genome in the womb has as yet unresolved ethical implications.

It could produce a wealth of data relating to a babys future health. At the same time, difficult questions may be raised about the moral case for termination.

Most pre-natal genetic screening currently involves tapping fluid from the foetal sac, or taking placental samples. Such invasive methods can only identify a small number of birth defects including Downs syndrome, and spina bifida.

They also pose risks for both mother and child. But there are thousands of rarer genetic conditions that are seldom spotted until they start producing symptoms.

The new research involved analysing DNA shed by the foetus and floating in the mothers bloodstream. Blood sample DNA from the mother was also studied as well as DNA extracted from the fathers saliva.

See the original post here:
Scientists map baby’s genetic code in womb

Recommendation and review posted by Bethany Smith

BACKGROUND: Tooth loss, although often associated with a diet high in sugar, has been a problem for as long as mankind has existed. Before the widespread use of refined sugar in food, tooth loss was often a result of disease and malnutrition, although dietary practices also contributed to the problem. Several studies have documented the negative aspects of not having teeth or dentures including impaired nutritional intake, lower self-confidence and self-esteem and reduced quality of life. The three most common tooth replacement options are dental implants, fixed bridges and removable appliances. (Source: perio.org)

STEM CELLS: Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell. (Source: The National Institutes of Health resource for stem cell research)

CLONING TEETH: Nova Southeastern Universitys dental researchers at the College of Dental Medicine are growing and harvesting human dental stem cells in the lab. The cells normally grow in flat layers of single cells in Petri dishes. To get them to form a 3-D tissue structure, researchers seed the cells on tissue engineering scaffolds made from the same polymer material as bio-resorbable surgical sutures. The scaffolds function like those you see around buildings under construction. They provide mechanical support and control the size and shape of a tissue. Once the stem cells are seeded on the scaffolds, researchers add growth factors to signal to the stem cells what type of tissue to grow. The combination of dental stem cells, tissue engineering scaffolds and growth factors allows researchers to engineer new tooth tissues. NSU scientists are working, similar tooth research labs, to create fully functional replacement teeth.

Dental researchers have been successful at regenerating teeth in the laboratory and in animals. They have developed a stem cell therapy for growing new teeth following root canal treatment, and also for replanting teeth that have been knocked out of the mouth. In NSUs technique for regenerating teeth, the pre-clinical trial subjects were able to eat and chew normally. No current studies have examined the ability of animals to eat using completely regenerated teeth because no one has yet regenerated all the teeth in an animal. In NSUs technique, the soft tissue, or pulp, inside teeth was removed and regenerated. The monkey subjects were able to use their teeth normally to eat and chew.

NSU is in the process of patenting a "regeneration kit" that will allow dentists to deliver stem cell therapies to replace dead tissue inside a tooth. In addition, several companies are collecting baby teeth to harvest stem cells through dental offices. The stem cells are being stored for future regenerative therapies, including growing new teeth or growing other replacement organs. (Source: NSU, Sun Sentinel)

The rest is here:
Cloning Teeth: Medicine’s Next Big Thing?

Recommendation and review posted by simmons